NEWS

Across global health systems, policymakers face a familiar but increasingly urgent challenge: managing rising health care costs without undermining the innovation and intellectual property systems that make future therapies possible.   Biopharmaceutical research is inherently long term . It requires substantial upfront investment and a stable intellectual property (IP) framework to ensure that successful products generate returns. When this balance is disrupted, the resulting

Last week, We Work For Health Executive Director Dan Leonard participated in a panel at the HealthCare Institute of New Jersey's (HINJ) 2026 Pulse: Saving Lives Globally, Driving Our Economy Locally  – a seminar designed to inform industry leaders, policymakers, and stakeholders about the state of New Jersey's life sciences sector and its leading role in advancing global health. The event took place at Middlesex College in Edison, New Jersey. New Jersey Governor Mikie Sherril

America remains the global leader in biopharmaceutical research and development, but an alarming climb from China over the past decade warrants a strategic response from U.S. policymakers, according to new research and recommendations from the Information Technology and Innovation Foundation.  The report compares private-sector R&D investments between U.S.- and China-headquartered firms across nine advanced industries, including pharmaceuticals and biotechnology, revealing a

America's biopharmaceutical leadership has never been more contested – or more consequential. As policymakers in Washington consider proposals like most favored nation (MFN), which would tie U.S. prices to European benchmarks, a critical question emerges: What actually happens when a country chooses cost containment over innovation?   Europe has lived that story.   The U.S. cannot afford to ignore how it ends.  On March 5, We Work For Health convened experts, industry leaders

We Work For Health's Executive Director Dan Leonard recently sat down with Dr. Robert Popovian, Chief Science Policy Officer at the Global Healthy Living Foundation and founder of Conquest Advisors, to discuss what's actually happening at the pharmacy counter now that the first Medicare-negotiated drug prices under the Inflation Reduction Act have taken effect.  Nearly two months into implementation, the picture emerging is far more complicated than the government's promises

For generations, the story of European pharmaceutical competitiveness has been one of stark decline,  providing a harsh lesson in what happens when price controls crowd out innovation. Europe's declining drug approval trajectory is a warning for U.S. policymakers  tempted by most-favored nation drug pricing. The decline has not gone unnoticed in Brussels. Motivated by years of self-inflicted setbacks, European leaders have begun to mount a serious campaign to reclaim the cont

During Rare Disease Week, the Senate Special Committee on Aging held a hearing  focused on the urgent need to strengthen the United States biomedical innovation ecosystem to benefit patients.   Lawmakers, advocates and industry leaders underscored a shared reality: for individuals living with rare and ultra-rare diseases, innovation represents both hope and the possibility of future access to treatment.   This moment calls attention to the scale of unmet medical need and to t

We Work For Health Executive Director Dan Leonard issued the following statement in response to President Trump’s call for the codification of Most Favored Nation price controls during his State of the Union Address.   “Last night, we heard again from the Administration about their plans to lower healthcare costs for American families – an admirable goal that has remained a priority for President Trump. We Work For Health shares the Administration's urgent desire to address t